NASDAQ:KURA Kura Oncology - KURA Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kura Oncology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $12.23 +0.37 (+3.12%) (As of 03/31/2023 12:00 AM ET) Add Compare Share Share Today's Range$11.85▼$12.2550-Day Range$10.71▼$14.6052-Week Range$10.30▼$19.93Volume432,314 shsAverage Volume637,775 shsMarket Capitalization$837.02 millionP/E RatioN/ADividend YieldN/APrice Target$31.20 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Kura Oncology MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside155.1% Upside$31.20 Price TargetShort InterestBearish11.00% of Float Sold ShortDividend StrengthN/ASustainability-0.76Upright™ Environmental ScoreNews Sentiment0.30Based on 2 Articles This WeekInsider TradingSelling Shares$73,270 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($2.38) to ($2.24) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.91 out of 5 starsMedical Sector704th out of 1,004 stocksPharmaceutical Preparations Industry350th out of 489 stocks 3.5 Analyst's Opinion Consensus RatingKura Oncology has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $31.20, Kura Oncology has a forecasted upside of 155.1% from its current price of $12.23.Amount of Analyst CoverageKura Oncology has only been the subject of 2 research reports in the past 90 days. Previous Next 0.0 Short Interest Percentage of Shares Shorted11.00% of the float of Kura Oncology has been sold short.Short Interest Ratio / Days to CoverKura Oncology has a short interest ratio ("days to cover") of 10.6, which indicates bearish sentiment.Change versus previous monthShort interest in Kura Oncology has recently increased by 0.14%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldKura Oncology does not currently pay a dividend.Dividend GrowthKura Oncology does not have a long track record of dividend growth. Previous Next 4.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreKura Oncology has received a 73.98% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Clinical research services for cancer", "Preclinical research services for physical health", and "Basic medical research services" products. See details.Environmental SustainabilityThe Environmental Impact score for Kura Oncology is -0.76. Previous Next 1.8 News and Social Media Coverage News SentimentKura Oncology has a news sentiment score of 0.30. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.51 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Kura Oncology this week, compared to 1 article on an average week. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Kura Oncology insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $73,270.00 in company stock.Percentage Held by InsidersOnly 5.40% of the stock of Kura Oncology is held by insiders. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Kura Oncology are expected to grow in the coming year, from ($2.38) to ($2.24) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Kura Oncology is -6.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Kura Oncology is -6.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioKura Oncology has a P/B Ratio of 1.95. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Kura Oncology (NASDAQ:KURA) StockKura Oncology, Inc. operates as a clinical-stage biopharmaceutical company, which engages in the research and development of medicines for the treatment of cancer. Its pipeline includes Tipifarnib, which is a Farnesyl transferase inhibitor for HRAS Mutant Solid Tumors, Chronic Myelomonocytic Leukemia, KO-947, which is an ERK inhibitor for MAPK Pathway Tumors, and KO-539, which is a Menin MLL inhibitor for acute leukemias. The company was founded by Troy E. Wilson, Yi Liu, Pingda Ren and Antonio Gualberto on August 22, 2014 and is headquartered in San Diego, CA.Read More Receive KURA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Kura Oncology and its competitors with MarketBeat's FREE daily newsletter. Email Address KURA Stock News HeadlinesMarch 30, 2023 | markets.businessinsider.comBrookline Capital Markets Reaffirms Their Buy Rating on Moderna (MRNA)March 28, 2023 | markets.businessinsider.comSVB Securities Sticks to Its Buy Rating for Kura Oncology (KURA)April 1, 2023 | Legacy Research (Affiliate) (Ad)Sell every Stock except ONE Markets are down...But Jeff Clark couldn't care less because he ignores almost every stock in the market except ONE. He lives financially free trading this One Stock Once per month...March 24, 2023 | americanbankingnews.comBrokerages Set Kura Oncology, Inc. (NASDAQ:KURA) PT at $31.50March 19, 2023 | markets.businessinsider.comGeron (GERN) Gets a Buy from WedbushMarch 14, 2023 | finance.yahoo.comKura Oncology Announces Acceptance of Two Abstracts for Presentation at AACR Annual MeetingMarch 1, 2023 | finance.yahoo.comKura Oncology to Participate in Upcoming Investor ConferencesFebruary 26, 2023 | finance.yahoo.comKura Oncology, Inc. (NASDAQ:KURA) Q4 2022 Earnings Call TranscriptApril 1, 2023 | Behind the Markets (Ad)Buy THIS stock before Taiwan is attacked... If the United States goes to war with another nuclear armed superpower, this could have a devastating impact on your retirement portfolio. Now, even Taiwan's own foreign minister is saying that China is on the cusp of a full scale invasion. But the good news is, if China invades Taiwan, there is a way to protect yourself.February 25, 2023 | seekingalpha.comKura Oncology, Inc. (KURA) Q4 2022 Earnings Call TranscriptFebruary 24, 2023 | finance.yahoo.comQ4 2022 Kura Oncology Inc Earnings CallFebruary 23, 2023 | finance.yahoo.comKura Oncology Reports Fourth Quarter and Full Year 2022 Financial ResultsFebruary 22, 2023 | benzinga.comKura Oncology's Earnings OutlookFebruary 17, 2023 | finance.yahoo.comKura Oncology to Report Fourth Quarter and Full Year 2022 Financial ResultsFebruary 16, 2023 | finance.yahoo.comKura Oncology to Report Fourth Quarter and Full Year 2022 Financial ResultsFebruary 9, 2023 | finance.yahoo.comKura Oncology Announces First Patients Dosed in Phase 2 Registration-Directed Trial of Ziftomenib in NPM1-Mutant Acute Myeloid LeukemiaFebruary 7, 2023 | finance.yahoo.comKura Oncology to Participate in SVB Securities Global Biopharma ConferenceJanuary 24, 2023 | seekingalpha.comKura Oncology: Good Cash, Some Good Data, A Few ProblemsJanuary 24, 2023 | baystreet.caKura Wins FDA Clearance for Tumor TreatmentJanuary 24, 2023 | markets.businessinsider.comH.C. Wainwright Keeps Their Buy Rating on Kura Oncology (KURA)January 24, 2023 | finance.yahoo.comKura Oncology Announces FDA Clearance of IND Application for KO-2806, a Next-Generation Farnesyl Transferase InhibitorJanuary 12, 2023 | benzinga.comCramer Is Holding This Biotech StockJanuary 11, 2023 | cnbc.comCramer's lightning round: I would hold onto Biomarin PharmaceuticalJanuary 6, 2023 | finance.yahoo.comAn Intrinsic Calculation For Kura Oncology, Inc. (NASDAQ:KURA) Suggests It's 48% UndervaluedDecember 20, 2022 | finance.yahoo.comKura Oncology Shares Fall After Updated Ziftomenib Data At ASH MeetingDecember 10, 2022 | finance.yahoo.comKura Oncology Presents Updated Clinical Data from KOMET-001 Trial of Menin Inhibitor Ziftomenib at American Society of Hematology Annual MeetingDecember 1, 2022 | finance.yahoo.comKura Oncology to Host Investor Event on December 10, 2022See More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive KURA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Kura Oncology and its competitors with MarketBeat's FREE daily newsletter. Email Address KURA Company Calendar Last Earnings2/23/2023Today4/01/2023Next Earnings (Estimated)5/03/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:KURA CUSIPN/A CIK1422143 Webwww.kuraoncology.com Phone(858) 500-8800FaxN/AEmployees121Year FoundedN/APrice Target and Rating Average Stock Price Forecast$31.20 High Stock Price Forecast$40.00 Low Stock Price Forecast$25.00 Forecasted Upside/Downside+155.1%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($2.03) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-135,840,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-30.77% Return on Assets-28.99% Debt Debt-to-Equity Ratio0.02 Current Ratio18.56 Quick Ratio18.56 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$6.28 per share Price / Book1.95Miscellaneous Outstanding Shares68,440,000Free Float64,743,000Market Cap$837.02 million OptionableOptionable Beta0.93 Key ExecutivesTroy E. WilsonChairman, President, CEO & Chief Financial OfficerKathleen FordChief Operating OfficerStephen DaleChief Medical OfficerMollie LeoniSenior Vice President-Clinical DevelopmentThomas DoyleChief Accounting Officer & Senior VP-FinanceKey CompetitorsEnanta PharmaceuticalsNASDAQ:ENTACymaBay TherapeuticsNASDAQ:CBAYCrinetics PharmaceuticalsNASDAQ:CRNXImmunoGenNASDAQ:IMGNCollegium PharmaceuticalNASDAQ:COLLView All CompetitorsInsiders & InstitutionsMetLife Investment Management LLCBought 946 shares on 3/23/2023Ownership: 0.052%Victory Capital Management Inc.Bought 161,429 shares on 3/10/2023Ownership: 2.220%Alliancebernstein L.P.Sold 167,245 shares on 2/16/2023Ownership: 0.120%Point72 Middle East FZEBought 9,243 shares on 2/16/2023Ownership: 0.014%Belvedere Trading LLCBought 200 shares on 2/15/2023Ownership: 0.000%View All Insider TransactionsView All Institutional Transactions KURA Stock - Frequently Asked Questions Should I buy or sell Kura Oncology stock right now? 5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Kura Oncology in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" KURA shares. View KURA analyst ratings or view top-rated stocks. What is Kura Oncology's stock price forecast for 2023? 5 brokers have issued 12 month price targets for Kura Oncology's stock. Their KURA share price forecasts range from $25.00 to $40.00. On average, they predict the company's share price to reach $31.20 in the next year. This suggests a possible upside of 155.1% from the stock's current price. View analysts price targets for KURA or view top-rated stocks among Wall Street analysts. How have KURA shares performed in 2023? Kura Oncology's stock was trading at $12.41 at the beginning of 2023. Since then, KURA stock has decreased by 1.5% and is now trading at $12.23. View the best growth stocks for 2023 here. When is Kura Oncology's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 3rd 2023. View our KURA earnings forecast. How were Kura Oncology's earnings last quarter? Kura Oncology, Inc. (NASDAQ:KURA) announced its quarterly earnings results on Thursday, February, 23rd. The company reported ($0.49) EPS for the quarter, beating analysts' consensus estimates of ($0.58) by $0.09. What ETFs hold Kura Oncology's stock? ETFs with the largest weight of Kura Oncology (NASDAQ:KURA) stock in their portfolio include Virtus LifeSci Biotech Clinical Trials ETF (BBC), ALPS Medical Breakthroughs ETF (SBIO), SPDR S&P Biotech ETF (XBI), Direxion Daily S&P Biotech Bull 3x Shares (LABU), Principal Healthcare Innovators ETF (BTEC), iShares Biotechnology ETF (IBB), Invesco Nasdaq Biotechnology ETF (IBBQ).ProShares Ultra Nasdaq Biotechnology (BIB). What other stocks do shareholders of Kura Oncology own? Based on aggregate information from My MarketBeat watchlists, some companies that other Kura Oncology investors own include Exelixis (EXEL), Inovio Pharmaceuticals (INO), Viking Therapeutics (VKTX), SCYNEXIS (SCYX), VBI Vaccines (VBIV), Amarin (AMRN), Gilead Sciences (GILD), NVIDIA (NVDA), Corbus Pharmaceuticals (CRBP) and Advanced Micro Devices (AMD). What is Kura Oncology's stock symbol? Kura Oncology trades on the NASDAQ under the ticker symbol "KURA." How do I buy shares of Kura Oncology? Shares of KURA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Kura Oncology's stock price today? One share of KURA stock can currently be purchased for approximately $12.23. How much money does Kura Oncology make? Kura Oncology (NASDAQ:KURA) has a market capitalization of $837.02 million. The company earns $-135,840,000.00 in net income (profit) each year or ($2.03) on an earnings per share basis. How many employees does Kura Oncology have? The company employs 121 workers across the globe. How can I contact Kura Oncology? Kura Oncology's mailing address is 12730 HIGH BLUFF DRIVE SUITE 400, SAN DIEGO CA, 92130. The official website for the company is www.kuraoncology.com. The company can be reached via phone at (858) 500-8800 or via email at ir@kuraoncology.com. This page (NASDAQ:KURA) was last updated on 4/1/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.